Objective:To investigate the epidemiological characteristics of allergic rhinitis (AR) among adults in Yinchuan, focusing on its prevalence and associated risk factors in recent years.Methods:A cross-sectional epidemiological survey was conducted among adult residents in Yinchuan from June to October 2022, including three districts, two counties, and one city, to identify and analyze factors influencing the incidence of AR in the population.Results:A total of 3 345 individuals were surveyed, including 1 891 males (56.5%) and 1 454 females (43.5%). The overall AR prevalence was 17.2% (576/3 345). The self-reported prevalence was 16.2% (306/1 891) in males and 18.6% (270/1 454) in females, with no statistically significant difference ( χ2=3.29, P=0.07). The prevalence was significantly lower among the elderly (aged over 60 years) at 11.8% (60/509) compared to the middle-aged (aged 40-59 years) at 17.1% (202/1 183) and young adults (aged 18-39 years) at 19.0% (314/1 653, χ2=10.36, P=0.023). Han nationality had the highest self-reported prevalence (18.8%, 446/2 372), followed by other ethnic minorities (17.6%, 13/74), and Hui nationality (13.0%, 117/899; χ2=11.21, P=0.004). Regionally, Xingqing District had the highest self-reported prevalence at (19.5%, 188/964), followed by Jinfeng District (18.7%, 151/808), Lingwu City (17.5%, 58/332), Xixia District (14.9%, 78/522), Yongning County (14.3%, 49/342), and Helan County (13.8%, 52/377; χ2=35.68, P=0.038). In terms of disease severity, mild cases made up 55.4% (319/576), while moderate to severe cases constituted 44.6% (257/576). In terms of symptom characteristics, perennial AR patients accounted for 18.8% (108/576), seasonal AR patients accounted for 81.2% (468/576), and 25.7% (148/576) of self-reported AR patients had other allergic diseases. Regarding diagnosis and treatment, 38.7% (223/576) of patients underwent allergen tests, 65.1% (375/576) received medication, but 62.3% (359/576) reported symptoms persisting for 2-year post-treatment, 32.6% (188/576) reported uncontrolled symptoms, and 5% (29/576) experienced symptoms worsening. Conclusions:The study provides a preliminary understanding of the epidemiological characteristics of AR in Yinchuan. These findings provide a reference for formulating relevant public health policies, clarifying prevention and treatment strategies, and improving the prevention and control system for AR.

Objective:To assess the pharmacoeconomic benefits of using omalizumab in the treatment of seasonal allergic rhinitis (SAR) before the pollen season.Methods:This economic evaluation, which based on a prospective, randomized, controlled, open label, single center trial conducted in 2020, compared omalizumab treatment with standard medicine treatment in controlling SAR symptoms two weeks before autumn pollen season. Total nasal symptom scores (TNSS) were used as the effect index for cost-effectiveness analysis (CEA), with incremental cost-effectiveness ratio (ICER) calculated. Cost-utility analysis (CUA) was used to compare incremental cost-utility ratios (ICUR) between groups using 1.76 times of the national and Beijing per capita GDP as willingness-to-pay thresholds. The experimental group was divided into mild and moderate-severe groups for cost-effectiveness analysis.Results:CEA showed an ICER of 3 084.76 yuan/point. CUA revealed an ICUR of 554 288.39 yuan, exceeding 1.76 times of the 2020 national (126 417.28 yuan) and Beijing (288 918.08 yuan) per capita GDP. Therefore, omalizumab currently lacked economic advantage in both Beijing and nationwide. The moderate-severe subgroup had a lower ICUR (371 041.07 yuan/year) than the mild subgroup (1 436, 823.35 yuan/year). Omalizumab would gain economic advantage in Beijing if its cost dropped below 723.02 yuan/dose, and nationwide below 312.72 yuan/dose. For moderate-severe patients, the cost threshold for Beijing was 1 104.95 yuan/dose, and 482.45 yuan/dose nationwide.Conclusions:At its current price, a single pre-pollen season omalizumab injection (300 mg) offers no pharmacoeconomic advantage over conventional medication in improving SAR patients′ quality of life in Beijing and nationwide. However, omalizumab shows lower ICUR in moderate-severe SAR patients compared to mild cases.

Objective:To investigate the epidemiological characteristics of allergic rhinitis (AR) among adults in Yinchuan, focusing on its prevalence and associated risk factors in recent years.Methods:A cross-sectional epidemiological survey was conducted among adult residents in Yinchuan from June to October 2022, including three districts, two counties, and one city, to identify and analyze factors influencing the incidence of AR in the population.Results:A total of 3 345 individuals were surveyed, including 1 891 males (56.5%) and 1 454 females (43.5%). The overall AR prevalence was 17.2% (576/3 345). The self-reported prevalence was 16.2% (306/1 891) in males and 18.6% (270/1 454) in females, with no statistically significant difference ( χ2=3.29, P=0.07). The prevalence was significantly lower among the elderly (aged over 60 years) at 11.8% (60/509) compared to the middle-aged (aged 40-59 years) at 17.1% (202/1 183) and young adults (aged 18-39 years) at 19.0% (314/1 653, χ2=10.36, P=0.023). Han nationality had the highest self-reported prevalence (18.8%, 446/2 372), followed by other ethnic minorities (17.6%, 13/74), and Hui nationality (13.0%, 117/899; χ2=11.21, P=0.004). Regionally, Xingqing District had the highest self-reported prevalence at (19.5%, 188/964), followed by Jinfeng District (18.7%, 151/808), Lingwu City (17.5%, 58/332), Xixia District (14.9%, 78/522), Yongning County (14.3%, 49/342), and Helan County (13.8%, 52/377; χ2=35.68, P=0.038). In terms of disease severity, mild cases made up 55.4% (319/576), while moderate to severe cases constituted 44.6% (257/576). In terms of symptom characteristics, perennial AR patients accounted for 18.8% (108/576), seasonal AR patients accounted for 81.2% (468/576), and 25.7% (148/576) of self-reported AR patients had other allergic diseases. Regarding diagnosis and treatment, 38.7% (223/576) of patients underwent allergen tests, 65.1% (375/576) received medication, but 62.3% (359/576) reported symptoms persisting for 2-year post-treatment, 32.6% (188/576) reported uncontrolled symptoms, and 5% (29/576) experienced symptoms worsening. Conclusions:The study provides a preliminary understanding of the epidemiological characteristics of AR in Yinchuan. These findings provide a reference for formulating relevant public health policies, clarifying prevention and treatment strategies, and improving the prevention and control system for AR.

Objective:To assess the pharmacoeconomic benefits of using omalizumab in the treatment of seasonal allergic rhinitis (SAR) before the pollen season.Methods:This economic evaluation, which based on a prospective, randomized, controlled, open label, single center trial conducted in 2020, compared omalizumab treatment with standard medicine treatment in controlling SAR symptoms two weeks before autumn pollen season. Total nasal symptom scores (TNSS) were used as the effect index for cost-effectiveness analysis (CEA), with incremental cost-effectiveness ratio (ICER) calculated. Cost-utility analysis (CUA) was used to compare incremental cost-utility ratios (ICUR) between groups using 1.76 times of the national and Beijing per capita GDP as willingness-to-pay thresholds. The experimental group was divided into mild and moderate-severe groups for cost-effectiveness analysis.Results:CEA showed an ICER of 3 084.76 yuan/point. CUA revealed an ICUR of 554 288.39 yuan, exceeding 1.76 times of the 2020 national (126 417.28 yuan) and Beijing (288 918.08 yuan) per capita GDP. Therefore, omalizumab currently lacked economic advantage in both Beijing and nationwide. The moderate-severe subgroup had a lower ICUR (371 041.07 yuan/year) than the mild subgroup (1 436, 823.35 yuan/year). Omalizumab would gain economic advantage in Beijing if its cost dropped below 723.02 yuan/dose, and nationwide below 312.72 yuan/dose. For moderate-severe patients, the cost threshold for Beijing was 1 104.95 yuan/dose, and 482.45 yuan/dose nationwide.Conclusions:At its current price, a single pre-pollen season omalizumab injection (300 mg) offers no pharmacoeconomic advantage over conventional medication in improving SAR patients′ quality of life in Beijing and nationwide. However, omalizumab shows lower ICUR in moderate-severe SAR patients compared to mild cases.

【Objective】 To analyze the effects of different fortified feeding methods on nutritional metabolism and growth rate of preterm very low birth weight infants (VLBWI), in order to provide new clues for improving the prognosis of the preterm infants. 【Methods】 A total of 115 cases of premature VLBWI admitted to Department of Neonatology, The First Affiliated Hospital of Kunming Medical University from January 2019 to December 2020 were included in this study, and were divided into fortified breastfeeding group (HFM group), mixed feeding group, and premature formula feeding group (PF group) based on their feeding methods. The effects of different feeding methods on the nutritional metabolism and growth rate of premature VLBWI were analyzed. 【Results】 1) The hospitalization time of infants in the HFM group was shorter than that in PF group and mixed feeding group (t=7.185, 6.924, P<0.05). 2) The proportion of necrotizing enterocolitis (NEC) in the HFM group during hospitalization was lower than that in the PF group (P<0.05); the proportions of late onset septicemia(LOS) and extra uterine growth restriction(EUGR) in the HFM group during hospitalization were lower than those in the PF group (χ²=5.030, 4.147, P<0.05); the proportion of LOS was lower than that of the mixed feeding group(χ²=6.589, P<0.05). 3) During hospitalization, the proportions of abdominal distension, bloody stools and increased eosinophils in the HFM group were lower than those in the PF group (P<0.05), which in mixed feeding group was lower than those in PF group (Fisher exact test, P<0.05). 4) At discharge, the weight and length growth rate of the HFM group were higher than those of the mixed feeding group (t=3.722, 0.425, P<0.001) and the PF group (t =6.015, 0.496, P< 0.001). 【Conclusion】 Fortified breastfeeding can more effectively increase the growth rate of VLBWI in premature infants, improve nutritional metabolism, reduce complications and adverse feeding reactions related to premature infants, and is safer and more effective.

Objective:To investigate the efficacy and safety of a novel dose adjustment schedule based on subcutaneous immunotherapy (SCIT) after a 16 weeks delayed injection during the maintenance period.Methods:Sixty-eight patients with allergic rhinitis (AR) who received dust mite cluster SCIT and had interrupted treatment for more than 16 weeks during the maintenance period were recruited at Beijing TongRen Hospital, from July to September 2020. They were randomly divided into the novel schedule group ( n=34) and the guideline recommended schedule group ( n=34). In addition, 34 patients who received dust mite SCIT at the same period were selected as the continuous treatment group ( n=34). When receiving treatment again after delayed injection, the novel schedule group was injected directly with the initial dose of maintenance period (10 000 SQ), and the guideline recommended schedule group started the dosage accumulation again from the lowest dose (10 SQ), while the continuous treatment group was injected according to the original schedule. Changes in the combined symptom and medication score (CSMS) from baseline after 3 years of SCIT were used as the primary efficacy evaluation index. Local and systemic adverse events were recorded to evaluate safety. SPSS 23.0 was used for statistical analysis. Results:At the end of 3 years, CSMS in all three groups decreased significantly from baseline, and there was no significant difference in the 3-year change value of CSMS from baseline between the novel schedule group and the guideline recommended schedule group (-1.0±0.3 vs -1.3±0.4, P=0.655). There was also no significant difference in the change of CSMS between the two dose-adjusted groups and the continuous treatment groups (-0.8±0.3 vs -1.3±0.3, P=0.156). No systemic adverse events occurred between the novel schedule group and the guideline recommended schedule group after restarting treatment, and there was no significant difference in frequency of adverse events (0.5% vs 0.5%, P=0.698). Conclusion:There is no significant difference in efficacy and safety between the novel dose adjustment schedule and the recommended dose adjustment schedule when SCIT interrupted injection for more than 16 weeks. Furthermore, SCIT discontinuation of injection for more than 16 weeks doesn′t significantly impact on 3-year efficacy.

Many people affected by fragile X syndrome (FXS) and autism spectrum disorders have sensory processing deficits, such as hypersensitivity to auditory, tactile, and visual stimuli. Like FXS in humans, loss of Fmr1 in rodents also cause sensory, behavioral, and cognitive deficits. However, the neural mechanisms underlying sensory impairment, especially vision impairment, remain unclear. It remains elusive whether the visual processing deficits originate from corrupted inputs, impaired perception in the primary sensory cortex, or altered integration in the higher cortex, and there is no effective treatment. In this study, we used a genetic knockout mouse model (Fmr1^KO), in vivo imaging, and behavioral measurements to show that the loss of Fmr1 impaired signal processing in the primary visual cortex (V1). Specifically, Fmr1^KO mice showed enhanced responses to low-intensity stimuli but normal responses to high-intensity stimuli. This abnormality was accompanied by enhancements in local network connectivity in V1 microcircuits and increased dendritic complexity of V1 neurons. These effects were ameliorated by the acute application of GABA_A receptor activators, which enhanced the activity of inhibitory neurons, or by reintroducing Fmr1 gene expression in knockout V1 neurons in both juvenile and young-adult mice. Overall, V1 plays an important role in the visual abnormalities of Fmr1^KO mice and it could be possible to rescue the sensory disturbances in developed FXS and autism patients.
Animals ; Disease Models, Animal ; Fragile X Mental Retardation Protein/metabolism* ; Fragile X Syndrome/metabolism* ; Humans ; Mice ; Mice, Knockout ; Neurons/metabolism*

Chronic rhinosinusitis is a common disease in otorhinolaryngology, which has chronic inflammation in mucosa of nasal cavity and sinus. The mechanisms of chronic rhinosinusitis is still unknown. Recently, some studies show that tissue remodeling has important roles in chronic rhinosinusitis, and as a part of tissue remodeling, epithelial-mesenchymal transition also received high attention. Therefore, this review will summarize the present studies involve epithelial-mesenchymal transition and chronic rhinosinusitis, so as to provide reference for further exploring the pathogenesis of chronic sinusitis.

Objective To explore the relationships among college students' trait anger,violent attitude and aggressive behavior.Methods A total of 991 college students were surveyed with the Trait Anger Scale,the Violent Attitude Questionnaire and the Aggression Questionnaire.Results (1)College students' scores on trait anger,violent attitude and aggressive scales were 17.99±3.94,3.52±2.20 and 70.12±14.67,respectively.(2) There were significant correlations among college students' trait anger,violent attitude and aggressive behavior(r=0.172-0.835,P<0.01).(3) Trait anger had a direct impact on aggressive behavior,as well as indirect effects through violent attitude.The direct effect of trait anger on aggressive behavior was 0.53,the indirect effect of violent attitude was 0.13,the total effect was 0.66,and the indirect effect was 20%.(4)The experience of parenting violence moderated the mediating effect of voilent attitude,and violent attitude moderated trait anger and aggression in those who didn't experience parenting violence(β=0.28,P<0.01),while the mediating effect was not significant in those who experienced parenting violence(β=-0.24,P=0.23,SIE=-0.166,P=0.28).Conclusion Violent attitude partially mediates trait anger and aggressive behavior,which is moderated by experienced parenting violence.

OBJECTIVEIo compare the difference on the clinical efficacy in treatment of chronic nephritis albuminuria between acupuncture and moxibustion at "Xiasanhuang", DONG's extra points and benazepril hydrochloride so as to provide the effective therapeutic method for the treatment of chronic nephritis albuminuria. Methods One hundred and six cases of nephritis albuminuria were randomized into an acupuncture and moxibustion group and a western medication group, 53 cases in each one. In the acupuncture and moxibustion group, acupuncture and moxibustion were applied to "Xiasanhuang" (Tianhuang fuxue namely "shenguan", "Dihuang", "Renhuang"), once a day, the interval of 2 days once every 10 treatments. In the western medication group, benazepril hydrochloride was prescribed for oral administration, 5 to 10 mg each time, once a day. The treatment of 2 months made, one session in the two groups. After 1 session treatment, the clinical efficacy, red blood cell count (RBC) of urinary sediment, 24 h urine protein quantitation and creatinine clearance rate (Ccr) before and after treatment were observed in the two groups.

RESULTSThe total effective rate was 84. 9% (45/53) in the acupuncture and moxibustion group, superior to 52. 8% (28/53) in the western medication group (P<0. 01). After treatment, RBC of urinary sediment and 24 h urine protein quantitation were reduced as compared with those before treatment (P< 0. 01, P<0. 05), and the results in the acupuncture and moxibustion group were lower than those in the western medication group (P<0. 05, P<0. 01). After treatment, Ccr in the acupuncture and moxibustion group was higher than that before treatment (P<0. 05) and higher than that in the western medication group (P<0. 05). Ccr was not different significantly before and after treatment in the western medication group (P>0. 05).

CONCLUSIONAcupuncture and moxibustion at DONG's extra points (Xiasanhuang) reduce proteinuria and improve kidney, function in patients of chronic nephritis and the efficacy is better than that with benazepril hydrochloride.

Acupuncture Points ; Acupuncture Therapy ; Adult ; Aged ; Albuminuria ; therapy ; Chronic Disease ; therapy ; Female ; Humans ; Male ; Middle Aged ; Moxibustion ; Nephritis ; therapy ; Treatment Outcome ; Young Adult